Sökning: id:"swepub:oai:DiVA.org:uu-423771" >
Cost effectiveness ...
-
Andersson, MariaAstraZeneca Nordic Baltic, Södertälje, Sweden.
(författare)
Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid-dependent asthma in Sweden
- Artikel/kapitelEngelska2020
Förlag, utgivningsår, omfång ...
-
2020-05-13
-
TAYLOR & FRANCIS LTD,2020
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-423771
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423771URI
-
https://doi.org/10.1080/13696998.2020.1760285DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Aim: We investigated cost effectiveness of benralizumab vs. standard of care (SOC) plus oral corticosteroids (OCS) for patients with severe, eosinophilic OCS-dependent asthma in Sweden. Materials and methods: A three-state, cohort-based Markov model of data from three Phase III benralizumab clinical trials (ZONDA [NCT02075255], SIROCCO [NCT01928771], and CALIMA [NCT01914757]) was used to assess the incremental cost-effectiveness ratio of benralizumab vs. SOC plus OCS. Health outcomes were estimated in terms of quality-adjusted life-years (QALYs). The model included costs and disutilities associated with extrapolated OCS-related adverse events. Patients with severe asthma were defined as those receiving OCS >= 5 mg/day. Results: Benralizumab demonstrated a cost-effectiveness ratio vs. SOC plus OCS of 2018 Swedish Kronor (SEK) 366,855 (euro34,127) per QALY gained, based on increases of 1.33 QALYs and SEK 488,742 (euro45,344) per patient. Benralizumab treatment costs contributed most to incremental costs. The probability of benralizumab's being cost-effective with willingness-to-pay (WTP) thresholds between SEK 429,972 (euro40,000) and SEK 752,452 (euro70,000) ranged from 75% to 99%. Limitations: Potential limitations of these analyses include the use of combined data from three different clinical trials, a one-way sensitivity analysis that did not include mortality and transition estimates, and Observational & Pragmatic Research Institute (OPRI) data from the UK as a proxy of the Swedish health care system. Conclusions: The results of these analyses demonstrate that benralizumab has a high probability of being cost-effective compared with SOC plus OCS for a subgroup of patients with severe, eosinophilic asthma receiving regular OCS treatment and may support clinicians, payers and patients in making treatment decisions.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Janson, ChristerUppsala universitet,Lung- allergi- och sömnforskning(Swepub:uu)chrisjn
(författare)
-
Kristensen, ThomasAstraZeneca Nordic Baltic, Södertälje, Sweden.
(författare)
-
Szende, AgotaCovance, Leeds, W Yorkshire, England.
(författare)
-
Golam, SarowarAstraZeneca, BioPharmaceut R&D, Global Market Access & Pricing, Gothenburg, Sweden.
(författare)
-
AstraZeneca Nordic Baltic, Södertälje, Sweden.Lung- allergi- och sömnforskning
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Medical Economics: TAYLOR & FRANCIS LTD23:8, s. 877-8841369-69981941-837X
Internetlänk
Hitta via bibliotek
Till lärosätets databas